
Jeryl Hilleman
Intersect ENT | Menlo Park, California
Ms. Hilleman serves as CFO of Intersect ENT, a biotechnology firm. She has more than two decades of experience as CFO of both private and public companies, including taking four companies public. Most recently, Ms. Hilleman has provided independent financial and strategic consulting for biotech and cleantech companies. From 2008 to 2012, Ms.Hilleman served as CFO of Amyris, Inc., a multi-national, renewable products company based in California and Brazil. Prior to Amyris, Ms. Hilleman served as CFO of Symyx Technologies, a public company selling instruments, software and research services to pharmaceutical and chemical companies, and led the finance function at two public biotechnology companies, Geron Corporation and Cytel Corporation. Ms. Hilleman is also a member of the board of directors and chair of the audit committee of Xenoport (Nasdaq:XNPT). Ms. Hilleman holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.